⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Basal Cell Carcinoma Market Poised for Steady Growth Throughout Forecast Period (2025-2034) Driven by Novel Drug Approvals and Expanding Patient Pool | DelveInsight
prnewswire.com
VRCA
REGN
NVS
GENK
INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
prnewswire.com
NVS
Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer
globenewswire.com
AZN
NVS
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
prnewswire.com
CRNX
NVS
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight
globenewswire.com
LUN
LLY
AMGN
NVS
TEVA
ALLER
BHVN
DRREDDY
ABBV
IMPL
ZSAN
AXSM
AEON
IONS
CHRC
AZN
GSK
WSTN
Comanche Biopharma Appoints Richard Colvin, MD, PhD as Global Head of R&D and John McHutchison, AO, MD as Chairman and Director of Comanche Biopharma Australia
globenewswire.com
CBIO
BBIO
NVS
TUNE
VELI
ASMB
GILD
Prescription Drugs Market Poised for Substantial Growth, Driven by Novel Therapies and Evolving Regulatory Landscape: Reaching US$2.15 Trillion by 2032
prnewswire.com
MRK
PFE
RO
NVS
SNY
Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial
globenewswire.com
NVS
BIIB
Next-Generation Biologics and Biosimilars Market to Hit 251.13 billion Dollars by 2033 - Strategic Revenue Insights (SRI)
prnewswire.com
AMGN
PFE
RHHBY
NVS
MRK
LLY
Cystic Fibrosis Therapeutics Market Set to Reach USD 35.09 Billion by 2033 as Precision CFTR Modulator Therapies Transform Patient Outcomes
prnewswire.com
VRTX
RHHBY
NVS
TEVA
GILD